Skip to main content

Theriva Biologics, Inc.

corporate_fare Company Profile

Theriva Biologics, Inc.

TOVX·NYSE·Life Sciences·CIK 0000894158

Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. Following its March 2022 acquisition of Theriva Biologics, S.L. (formerly VCN Biosciences, S.L.), the company transitioned its strategic focus to oncology through development of VCN's new oncolytic adenovirus platform, designed for intravenous and intravitreal delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient's immune system. The lead product candidate, VCN-01 (zabilugene almadenorepvec), is a clinical-stage oncolytic human adenovirus modified for tumor-selective replication and to express an enzyme, PH20 hyaluronidase. VCN-01 has been evaluated in a Phase 2b clinical study for the treatment of pancreatic cancer ("VIRAGE"), a Phase 1 clinical study for the treatment of retinoblastoma, and various other Phase 1 clinical studies for the treatment of other solid tumors including head and neck squamous cell carcinoma. Prior to the acquisition, the company focused on developing therapeutics for gastrointestinal (GI) diseases, including two clinical development candidates: SYN-004 (ribaxamase), designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the GI tract to prevent microbiome damage, thereby preventing overgrowth and infection by pathogenic organisms such as Clostridioides difficile infection (CDI) and vancomycin resistant Enterococci (VRE), and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients; and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under current good manufacturing practices (cGMP) conditions and intended to treat both local GI and systemic diseases. In February 2026, the company entered into a license agreement (the "Rasayana License Agreement") with Rasayana Therapeutics, Inc.

Theriva Biologics, Inc. (NYSE:TOVX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 5 items for TOVX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 8/10. Across its 5 most recent items scored 7 or higher, the top rating is 8/10, with 3 rated 8 or above. Recent SEC coverage for TOVX spans 8-K, 10-Q.

Recent high-impact activity:

  • Theriva Sets 1-for-30 Reverse Split Effective December 1 to Regain NYSE American Compliance
  • Theriva Holders Approve 500M Authorized Shares and 16.2M Warrant-Share Issuance
  • Theriva 10-Q Reaffirms Going Concern: $8.5M Cash Lasts Only Into Q1 2027
  • Theriva Posts Q3 Loss of $1.5M, Cash Runway Into Q1 2027
  • Theriva Sells Ribaxamase Portfolio to Biossil for $350K Upfront, Up to $91M in Milestones

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$23.74M
Diluted EPS
-$2.08
Op. Cash Flow
-$16.67M
Free Cash Flow
-$16.7M
Operating Income
-$24.05M
Cash & Equivalents
$13.06M
Total Debt
$1.67M
Debt / Equity
0.11×
Shares Outstanding
35.69M sh
Source: 10-K · filed 2026-03-12 · accession 0001104659-26-026767

Short Interest & Short Volume

2.74 days to cover

FINRA reported short interest of 1,414,042 shares in TOVX as of the October 30, 2026 settlement, a 23.4% decrease from the prior period — about 2.7 days to cover at its recent average daily volume. On November 20, 2026, 30.9% of TOVX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)1,414,042 shares as of October 30, 2026
Change vs prior period▼ 23.4%
Days to cover2.74 at avg daily volume of 516,671
Daily short volume (FINRA facilities)30.9% of 340,680 shares on November 20, 2026
5-day average short volume38.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for TOVX, detected from its recent SEC filings · based on capital-structure filings through 2026-11-18.

Authorized Shares Raised to 500 Million · Warrant Share Issuance Ratified

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with T →
$0.0899 -25.08% today
52-week range · as of 2026-11-20 $0.0899 – $0.492
Market cap
$5.51M
Volume
1.4M (0.4× avg)
3-mo avg 3.7M
Live data · 2026-11-21 11:00 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed TOVX - Latest Insights

TOVX
Nov 20, 2026, 4:35 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.1186
Real-time Price: $0.0899 info
Change: -$0.0287 (-24%) info
Market Cap: $5.507M info
TOVX
Nov 18, 2026, 4:31 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.144
Real-time Price: $0.0899 info
Change: -$0.0541 (-38%) info
Market Cap: $5.507M info
TOVX
Nov 12, 2026, 8:15 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.160
Real-time Price: $0.0899 info
Change: -$0.0701 (-44%) info
Market Cap: $5.507M info
TOVX
Nov 12, 2026, 8:10 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.160
Real-time Price: $0.0899 info
Change: -$0.0701 (-44%) info
Market Cap: $5.507M info
TOVX
Nov 02, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.1802
Real-time Price: $0.0899 info
Change: -$0.0903 (-50%) info
Market Cap: $5.507M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets